Efficacy and safety of antigen-specific immunotherapy in the treatment of patients with non-small-cell lung cancer: a systematic review and meta-analysis.

CONCLUSION: Our study demonstrated the clinical survival benefits of tecemotide and TG4010 in the treatment of NSCLC. However, these evidences might be limited by potential biases. Therefore, further well-conducted, large-scale RCTs are needed to verify our findings.
PMID: 29714142 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - April 30, 2018 Category: Cancer & Oncology Authors: Yan BD, Cong XF, Zhao SS, Ren M, Liu ZL, Li Z, Chen C, Yang L Tags: Curr Cancer Drug Targets Source Type: research